BusinessVineti Completes $33.5 Million in Series B Financing to Accelerate Patient Access to Cell and Gene TherapiesBy Nasdaq OMXApr 16, 2018, 11:30 AM UTC
BusinessVineti expands its platform to support provision of American Red Cross allogeneic apheresis collections for cellular therapyBy Nasdaq OMXSep 6, 2017, 1:01 PM UTC
